Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the recipient of a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 70,257 shares, an increase of 51.2% from the July 30th total of 46,462 shares. Based on an average daily trading volume, of 679,339 shares, the short-interest ratio is currently 0.1 days. Currently, 14.5% of the company’s stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC lifted its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the period. Citadel Advisors LLC owned 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 58.41% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Scinai Immunotherapeutics currently has a consensus rating of “Sell”.

Scinai Immunotherapeutics Stock Up 0.8%

Shares of SCNI stock traded up $0.02 on Tuesday, reaching $2.52. 22,829 shares of the stock were exchanged, compared to its average volume of 152,879. The company has a market capitalization of $1.31 million, a price-to-earnings ratio of -0.24 and a beta of 2.08. The business’s 50 day moving average price is $2.60 and its 200 day moving average price is $4.78. The company has a current ratio of 1.56, a quick ratio of 1.35 and a debt-to-equity ratio of 0.05. Scinai Immunotherapeutics has a twelve month low of $2.15 and a twelve month high of $16.80.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.